Compare Microchip Technology Inc. (MCHP) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Neurocrine Biosciences Inc — how do they compare? Microchip Technology Inc. trades at $76.7 (market cap $41.01B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Microchip Technology Inc. is far larger — about 2.9× Neurocrine Biosciences Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MCHP | NBIX | |
|---|---|---|
Market Cap | $41.01B | $14.36B |
Volume | 9,972,516 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $102.97 | $185.50 |
52-Week Low | $49.02 | $123.10 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $46.13B | $14.37B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $78.02, down 3.99% on the day, amid a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue declined sharply in 2025 to $4.40B, resulting in a net loss, but 2026 projections show recovery. Analyst consensus is strongly bullish with a $110.50 price target. Recent news highlights expansion in Ethernet and power portfolios, plus the acquisition of Hailo to bolster edge AI capabilities.
MCHP's outlook is supported by robust analyst buy ratings and exposure to growing AI and data center demand. However, high valuation multiples, significant debt, and cyclical semiconductor risks pose challenges. Earnings growth in 2026 will be critical to justifying its premium valuation and driving shareholder returns.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
